Alivus Life, a company in the Pharmaceuticals industry, reported revenue of ₹682 crore and net profit of ₹197 crore for the September 2026 quarter.
Alivus Life (NSE: ALIVUS) closed at ₹1,436.90 on 20 Nov 2026, up 57.9% over the past year. Its market capitalisation is ₹17,669 crore and it trades at 25.7 times earnings.
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.